Heidelberg Pharma and Huadong Medicine strike licensing and investment agreement
The multimillion-dollar deal focuses on potential targeted cancer treatments and makes Huadong the strategic partner in Asia for Heidelberg Pharma’s product development
In a deal worth up to USD 930 million (EUR 825 million), Heidelberg Pharma has granted China's Huadong Medicine Co. exclusive license to develop and commercialise its two lead oncology candidates HDP-101 and HDP-103 in Asia, as well as exclusive opt-in rights for two more pipeline candidates.
The licensing deal covers Heidlberg Pharma's proprietary lead candidate HDP-101 is a B-cell maturation antigen (BCMA) antibody-targeted amanitin conjugate (ATAC) for multiple myeloma and its HDP-103, which is a PSMA ATAC for metastatic castration-resistant prostate cancer. Both are in clinical development.
ATACs, unlike standard therapeutics, are characterised by improved efficacy even on dormant tumour cells, which can contribute to tumour recurrence and resistance development.
The Germany-based biopharmaceutical company will receive an upfront payment of $20 million (€17.5 million) and milestone payments of up to $449 million (€400 million), and tiered royalties for each candidate.
The oncology specialist has also granted Huadong an exclusive option for the pre-IND research candidates HDP-102 (CD37-ATAC) for non-Hodgkin's lymphoma and HDP-104 (undisclosed target) in Asia (excluding India, Japan, Pakistan, Sri Lanka) with a total deal value of up to $461 million (€410 million).
In addition, the Chinese pharmaceutical company will also become the strategic partner in Asia for Heidelberg Pharma’s product development.
As part of the investment agreement Huadong intends to make an equity investment in Heidelberg Pharma totaling €105 million, representing 35% of total shares outstanding and therefore making it the second largest shareholder (dievini Hopp BioTech holding GmbH remains largest shareholder).
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance